{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'APPENDIX 13. 6-MINUTE WALK TEST (6MWT)', 'A 6MWT will be performed to assess the distance a subject is able to walk in six minutes on a', 'fixed course length. The subject will be instructed to walk as far as possible for 6 minutes.', 'Subjects may stop to rest as needed but should continue walking as soon as they are able.', 'If a test is unusable the Core Lab will instruct the site to repeat the test, if possible.', 'CPC Clinical Research (CPC) will provide training to all individuals who will be administering', 'the 6MWT for this trial and pre-approving the 6MWT course at each clinical site. Subjects', 'should only be walked on a course that is approved by CPC.', 'The following instructions should be provided to the subject prior to each visit that includes a', '6MWT:', '1. Do not eat or smoke within 1 hour prior to the test,', '2. Wear comfortable, low-heeled walking shoes for the test, and', '3. Bring your usual walking aid (cane, walker, etc.) with you to the visit.', 'Please refer to the Study Manual and CPC 6MWT Reference Tool for the full instruction on how', 'to conduct the 6MWT.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '117']['SPIMM-301 Version 4.0', '15 June 2018', 'APPENDIX 14. TABLE FOR GRADING THE SEVERITY OF INJECTION', 'SITE REACTIONS', 'GRADE 4', 'GRADE 1', 'GRADE 2', 'GRADE 3', 'POTENTIALLY', 'PARAMETER', 'MILD', 'MODERATE', 'SEVERE', 'LIFE-', 'THREATENING', 'Injection Site', 'Pain or', 'Pain or tenderness', 'Pain or', 'Pain or tenderness', 'Pain or', 'tenderness', 'causing greater than', 'tenderness', 'causing inability to', 'Tenderness', 'causing no or', 'minimal limitation', 'causing inability', 'perform basic self-care', 'minimal', 'of use of limb', 'to perform', 'function OR', 'limitation of use', 'usual social', 'Hospitalization', 'of limb', '& functional', 'indicated', 'activities', 'Injection Site', '2.5 to < 5 cm in', '> 5 to < 10 cm in', '> 10 cm in', 'Potentially life-', 'Erythema or', 'diameter OR 6.25', 'diameter OR > 25 to <', 'diameter OR:', 'threatening', 'Redness', 'to < 25 cm\u00b2 surface', '100 cm\u00b2 surface', '100 cm\u00b2 surface', 'consequences (eg,', 'area AND', 'area OR Symptoms', 'area OR', 'abscess,', 'Symptoms causing', 'causing greater than', 'Ulceration OR', 'exfoliative', 'no or minimal', 'minimal', 'Secondary', 'dermatitis,', 'interference with', 'interference with', 'infection OR', 'necrosis', 'usual social &', 'usual social &', 'Phlebitis OR', 'involving dermis', 'functional', 'functional activities', 'Sterile abscess', 'or deeper tissue)', 'activities', 'OR Drainage OR', 'Symptoms', 'causing inability', 'to perform usual', 'social &', 'functional', 'activities', 'Injection Site', 'Same as for', 'Same as for', 'Same as for', 'Same as for', 'Induration or', 'Injection Site', 'Injection Site', 'Injection Site', 'Injection Site', 'Swelling', 'Erythema or', 'Erythema or', 'Erythema or', 'Erythema or', 'Redness', 'Redness', 'Redness', 'Redness', 'Injection Site', 'Itching localized to', 'Itching beyond the', 'Generalized', 'NA', 'Pruritus', 'the injection site', 'injection site that is', 'itching causing', 'that is relieved', 'not generalized OR', 'inability to', 'spontaneously or in', 'Itching localized to', 'perform usual', '< 48 hours of', 'the injection site', 'social', 'treatment', 'requiring > 48', '& functional', 'hours treatment', 'activities', 'Adapted from Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events,', 'Version 2.0, November 2014.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '118']['SPIMM-301 Version 4.0', '15 June 2018', 'APPENDIX 15. COUNTRY-SPECIFIC APPENDIX--GERMANY', 'The SAE definition and reporting of SAEs will conform to the Medical Devices Safety Plan', 'Ordinance (Medizinprodukte-Sicherheitsplanverordnung) that is valid for Germany.', 'SAE definition:', '\"Ein Schwerwiegendes unerw\u00fcnschtes Ereignis\" ist jedes in einer genehmigungspflichtigen', 'klinischen Pr\u00fcfung oder einer genehmigungspflichtigen Leistungsbewertungspr\u00fcfung auftretende', 'ungewollte Ereignis, das unmittelbar oder mittelbar zum Tod oder zu einer schwerwiegenden', 'Verschlechterung des Gesundheitszustands eines Probanden, eines Anwenders oder einer', 'anderen Person gef\u00fchrt hat, gef\u00fchrt haben k\u00f6nnte oder f\u00fchren k\u00f6nnte ohne zu ber\u00fccksichtigen,', 'ob das Ereignis vom Medizinprodukt verursacht wurde; das Vorgesagte gilt entsprechend f\u00fcr', 'schwerwiegende unerw\u00fcnschte Ereignisse, die in einer klinischen Pr\u00fcfung oder', 'Leistungsbewertungspr\u00fcfung, f\u00fcr die eine Befreiung von der Genehmigungspflicht nach \u00a7 20', 'Absatz 1 Satz 2 des Medizinproduktegesetzes erteilt wurde, aufgetreten sind.', 'SAE reporting responsibilities for Germany are detailed in the SMP.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '119']\n\n###\n\n", "completion": "END"}